Clinical Trial

A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Sponsor decided to discontinue development of the compound
Summary
ONO-7018 is a selective inhibitor of mucosa associated lymphoid tissue protein 1 (MALT1) and is expected to exhibit antitumor activity in NHL. This study is Phase1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (biomarkers) and efficacy of ONO-7018 in patients with relapsed or refractory NHL.
Protocol Amendment History 5 changes
critical Trial terminated 2026-07-30
critical Trial terminated: Sponsor decided to discontinue development of the compound 2026-07-30
notable Enrollment reduced: 24 -> 2 participants 2026-07-30
notable Primary completion moved earlier: 2027-07-31 -> 2026-04-28 2026-07-30
minor Completion moved earlier: 2029-12-31 -> 2026-04-28 2026-07-30
Trial Details
NCT Number NCT06622226
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Non Hodgkin Lymphoma
Enrollment 2 participants
Start Date 2024-11-27
Primary Completion 2026-04-28 (estimated)
Study Completion 2026-04-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-29